The FDA previously hadn’t ever accepted an application of a drug like fenebrutinib in two major forms of MS. But safety ...

A spokesperson confirmed that a “limited number” of liver-related safety events, including a patient death, were observed in ...

Analysts guessed that investors wanted to see stronger durability results at a four-year check-in of the key trial supporting ...

Children should have the freedom to focus on school, friendships, family, sports, birthdays, and simply growing up. Yet ...

Discovery remains essential, but its value depends on builders and systems capable of carrying it through. The organizations ...

Beam claimed a former scientist stole confidential information and quietly spun up a rival rare disease treatment at YolTech ...

Rather than deplete malfunctioning B cells as many other emerging autoimmune drugs do, Ai3Bio’s therapies are designed to ...

Novo’s latest alliance involves injectables given every one to three months. Elsewhere, Nektar won a legal spat with Eli ...

The equity investment comes alongside a deal to test Summit’s ivonescimab alongside potentially many AstraZeneca drugs — but ...

The government has announced “most-favored-nation” pricing agreements with 26 pharma companies. But the deals could stymie other plans to lower the country’s spending on prescription drugs.

The Phase 3 findings suggested Kodiak might have multiple threats to Regeneron’s Eylea and added more than $3 billion to the ...

In an interview with BioPharma Dive, Compass executives said that, should the FDA approve their treatment, they hope to capitalize on a strategy pioneered by J&J in selling the ketamine spray Spravato ...